Evaluation of Third-line cART Regimen in Cambodia (3DICAM)
Status:
Recruiting
Trial end date:
2022-04-11
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the virological effectiveness of a third-line regimen combining
dolutegravir (DTG), ritonavir-boosted darunavir (DRV/r) and optimized NRTI in Cambodian
HIV-infected adults, who failed a protease inhibitors (PI)-based second-line regimen despite
3 months of boosted adherence counseling (BAC).
Phase:
Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)